Article
Medicine, General & Internal
Salvatore D'Angelo, Fabiola Atzeni, Maurizio Benucci, Gerolamo Bianchi, Fabrizio Cantini, Roberto Felice Caporali, Giorgio Carlino, Francesco Caso, Alberto Cauli, Francesco Ciccia, Maria Antonietta D'Agostino, Lorenzo Dagna, Christian Dejaco, Oscar Massimiliano Epis, Maria Grazia Ferrucci, Franco Franceschini, Enrico Fusaro, Marco Gabini, Roberto Gerli, Roberto Giacomelli, Marcello Govoni, Elisa Gremese, Giuliana Guggino, Annamaria Iagnocco, Florenzo Iannone, Bruno Lagana, Ennio Lubrano, Carlomaurizio Montecucco, Rosario Peluso, Roberta Ramonda, Maurizio Rossini, Carlo Salvarani, Gian Domenico Sebastiani, Marco Sebastiani, Carlo Selmi, Enrico Tirri, Antonio Marchesoni
Summary: This study aims to provide helpful insights for the management of PsA, addressing the unresolved issues of this disease.
FRONTIERS IN MEDICINE
(2023)
Review
Immunology
Gilbert Donders, Istvan Oszkar Sziller, Jorma Paavonen, Phillip Hay, Francesco de Seta, Jean Marc Bohbot, Jan Kotarski, Jordi Antoni Vives, Bela Szabo, Ramona Cepuliene, Werner Mendling
Summary: Recurrent vulvovaginal candidosis (RVVC) is a chronic and difficult to treat vaginal infection caused by Candida species. Fluconazole resistance and the rising prevalence of non-albicans Candida species pose challenges in treatment. Innovative strategies and research into new drugs and the impact of RVVC on patients' quality of life and sex life are needed.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Oncology
Vikram Mathews, Anu Korula, Anupam Chakrapani, Dinesh Bhurani, Jina Bhattacharyya, Manju Sengar, Pankaj Malhotra, Pavan Kumar Boyella, Pawan Kumar Singh, Prasanth Ganesan, Rishi Dhawan, Sameer Melinkeri, Sharat Damodar, Tuphan Kanti Dolai, Venkatraman Radhakrishnan
Summary: This article aims to provide guidelines for the management and treatment of B-ALL in Indian settings. Through expert consensus and discussions, recommendations for diagnosis, frontline treatment, and choice of therapy in relapsed/refractory settings were made. The article summarizes important recommendations for the diagnosis and treatment of B-ALL, providing valuable guidance for clinicians in India.
FRONTIERS IN ONCOLOGY
(2023)
Review
Endocrinology & Metabolism
Selcuk Dagdelen, Oguzhan Deyneli, Nevin Dinccag, Hasan Ilkova, Zeynep Osar Siva, Ilhan Yetkin, Temel Yilmaz
Summary: This guidance document provides recommendations and a practical algorithm for healthcare providers to use a standardized glucose reporting system in routine diabetes care, addressing the rationale and analysis methods for the new standardized glucose reporting system based on innovative continuous glucose monitoring techniques.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Respiratory System
Laren D. Tan, Abdullah Alismail, Barbara Ariue
Summary: This article reviews the subtle differences and similarities between the asthma treatment recommendations of NAEPP 2020 and GINA 2021, providing evidence-based suggestions for the management of asthma. It equips healthcare providers with the best and most updated knowledge on asthma care.
CURRENT OPINION IN PULMONARY MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jennifer S. Golia S. Pernicka, Gaiane M. Rauch, Natalie Gangai, David D. B. Bates, Randy Ernst, Thomas A. Hope, Natally Horvat, Shannon P. Sheedy, Marc J. Gollub
Summary: The role and method of image-based staging of anal cancer has changed with the development of new imaging modalities. There is great variability in imaging practices and guidelines for anal cancer compared to nearby rectal cancer. A literature review was conducted to understand the benefits of new imaging technologies, followed by a survey among abdominal radiologists to obtain expert opinions on the appropriate imaging strategy for anal cancer.
ABDOMINAL RADIOLOGY
(2023)
Letter
Rheumatology
Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Martin Schaefer, Anja Strangfeld, Kimme L. Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Laure Gossec, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Robert B. M. Landewe, Denis Poddubnyy, Proton Rahman, Filip E. Van den Bosch, Rebecca Bolce, Soyi Liu Leage, Jeffrey R. Lisse, So Young Park, Lianne Gensler
Summary: In patients with axial spondyloarthritis who flared after withdrawal of IXE therapy, retreatment with open-label IXE can recapture a certain proportion of patients achieving low disease activity (LDA) or inactive disease (ID).
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Health Care Sciences & Services
Helena Santos, Ana Rita Henriques, Jaime Branco, Pedro M. Machado, Helena Canhao, Fernando M. Pimentel-Santos, Ana Maria Rodrigues
Summary: The study found that both spondyloarthritis and chronic low back pain have similar impacts on health-related quality of life (HRQoL), including mental, physical, and social domains. Patients with spondyloarthritis and chronic low back pain reported significantly lower HRQoL compared to those without rheumatic diseases. Modifiable factors such as multimorbidity, active disease, obesity, and regular physical exercise were associated with HRQoL in these conditions.
QUALITY OF LIFE RESEARCH
(2023)
Review
Rheumatology
Dafne Capelusnik, Diego Benavent, Desiree van der Heijde, Robert Landewe, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compan, Sofia Ramiro
Summary: This study conducted a systematic literature review to summarize the relationship between early treatment and treatment clinical response in patients with SpA. It found that early treatment was associated with better outcomes in patients with non-radiographic axSpA and symptom duration of less than 5 years, but no differences in response to treatment were found in radiographic axSpA or in patients with longer symptom duration.
Article
Rheumatology
Casper Webers, Uta Kiltz, Juergen Braun, Desiree van der Heijde, Annelies Boonen
Summary: Treating active SpA improves depressive symptoms, especially with TNF inhibitors (TNFis) which have a stronger effect mainly due to their impact on disease activity.
Article
Orthopedics
Daniela Costa, Eduardo B. Cruz, David G. Lopes, Catarina Nunes da Silva, Ana Rita Henriques, Diogo Luis, Jaime Branco, Helena Canhao, Ana M. Rodrigues
Summary: Pain due to knee and/or hip osteoarthritis is a common reason for seeking healthcare. This study aimed to estimate the prevalence of unmanageable pain levels among people with osteoarthritis, identify factors associated with unmanageable pain, and compare therapeutic strategies used by individuals with unmanageable pain versus manageable pain.
BMC MUSCULOSKELETAL DISORDERS
(2023)
Article
Medicine, General & Internal
Iain B. McInnes, Akihiko Asahina, Laura C. Coates, Robert Landewe, Joseph F. Merola, Christopher Ritchlin, Yoshiya Tanaka, Laure Gossec, Alice B. Gottlieb, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Philip J. Mease
Summary: This study evaluated the efficacy and safety of Bimekizumab in patients with active psoriatic arthritis who were naive to biologic DMARDs. The results showed that Bimekizumab treatment had superior improvements in joint, skin, and radiographic efficacy outcomes compared with placebo, and the safety profile was consistent with previous studies.
Article
Medicine, General & Internal
Joseph F. Merola, Robert Landewe, Iain B. McInnes, Philip J. Mease, Christopher T. Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D. Gladman, Laure Gossec, Alice B. Gottlieb, Diamant Thaci, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Summary: This study compared the efficacy and safety of Bimekizumab with placebo in patients with active psoriatic arthritis. The results showed that Bimekizumab treatment led to superior improvements in joint and skin efficacy outcomes compared with placebo. The safety profile of Bimekizumab was consistent with previous studies.
Letter
Rheumatology
Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B. M. Landewe, Desiree van der Heijde
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Multidisciplinary Sciences
Luis Antunes Gomes, Ana Maria Rodrigues, Jaime Branco, Helena Canhao, Eduardo Brazete Cruz
Summary: This study aimed to investigate the courses of chronic low back pain (CLBP), its cumulative impact, and the indicators for the persistence of pain. The results showed that patients with CLBP could follow a persistent or relapsing course of pain in the long-term. Being female, presenting depressive symptoms, having a manual job, and higher disability at baseline were predictors of a persistent course of LBP.
Article
Rheumatology
Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, Paul Emery, Pascal Hendrik Pieter de Jong, Robert B. M. Landewe, Willem Lems, Josef S. Smolen, Tom W. J. Huizinga, Cornelia F. Allaart, Sytske Anne Bergstra
Summary: In patients with rheumatoid arthritis (RA), the use of glucocorticoids (GC) as bridging therapy resulted in a more rapid clinical improvement and fewer changes in medication, but similar long-term GC use compared with patients who did not receive bridging therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Correction
Rheumatology
Janne W. Bolt, Caroline J. Aalbers, Laura Walet, Leonieke J. J. van Mens, Christiaan van Denderen, Irene van der Horst-Bruinsma, Lisa G. M. van Baarsen, Robert Landewe, Marleen G. H. van de Sande
Article
Rheumatology
Teresa Oton, Loreto Carmona, Jose Luis Andreu
Summary: This study assessed the experience and needs of patients receiving MTX treatment through an online survey. The results showed that patients were not satisfied with the quality of information provided by clinics and had a demand for more and better-quality written or web-based information.
RHEUMATOLOGY INTERNATIONAL
(2023)